Timing of Apixaban Withhold Prior to Ureteric Stenting
For ureteric stent placement, apixaban should be withheld for 48 hours (2 days) before the procedure, and can be safely restarted 48-72 hours after the procedure once hemostasis is established. 1
Pre-Procedure Management
Standard Interruption Protocol
Withhold apixaban 48 hours (2 days) before ureteric stenting. This recommendation is based on:
- FDA labeling explicitly states apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with moderate or high risk of bleeding 1
- Ureteric stenting carries intermediate bleeding risk due to urinary tract instrumentation and potential for hematuria
- The 48-hour interruption allows approximately 4 half-lives to elapse (apixaban half-life ~12 hours), resulting in minimal residual anticoagulant effect 2
This aligns with the 2014 Canadian Cardiovascular Society guidelines recommending apixaban interruption 2-3 days before procedures with intermediate or high bleeding risk 3.
Renal Function Considerations
If creatinine clearance is 30-50 mL/min, extend the interruption to 72 hours (3 days) before the procedure. 2
Apixaban has 27% renal clearance, and moderate renal impairment prolongs the elimination half-life, requiring longer interruption periods to ensure adequate drug clearance 4.
No Bridging Required
Do not use bridging anticoagulation (LMWH or UFH) during the interruption period. 1
The FDA label explicitly states bridging is "not generally required" during the 24-48 hour interruption period. The short half-life of apixaban makes bridging unnecessary for most patients.
Post-Procedure Management
Resumption Timing
Restart apixaban 48-72 hours after ureteric stenting once adequate hemostasis is established. 3
The specific timing depends on:
- 48 hours post-procedure: If minimal bleeding and good hemostasis
- 72 hours post-procedure: If there are concerns about bleeding or if hemostasis is not completely secure
This conservative approach is supported by:
- Canadian guidelines recommending resumption "1 day after hemostasis is established (usually 48 hours for low risk procedures and 72 hours for intermediate/high risk procedures)" 3
- Blood journal guidelines suggesting 48-72 hours for high bleeding risk procedures 2
Full Dose Resumption
Resume at full therapeutic dose (5 mg twice daily or 2.5 mg twice daily if dose-reduced)—do not use prophylactic dosing. 2
Unlike some other DOACs, apixaban does not require a gradual dose escalation. The rapid onset of action (peak effect in 3-4 hours) means full anticoagulation is achieved quickly 4.
Important Caveats
Urological-Specific Considerations
While the urological literature 5 discusses anticoagulation management for various urological procedures, it provides limited specific guidance on ureteric stenting. The procedure should be classified as intermediate bleeding risk given:
- Urinary tract instrumentation
- Potential for significant hematuria
- Risk of stent-related bleeding complications
Patient-Specific Factors Requiring Longer Interruption
Consider extending pre-procedure interruption beyond 48 hours if:
- Severe renal impairment (CrCl <30 mL/min): Extend to 4 days 2
- Concurrent P-gp or CYP3A4 inhibitors: May prolong apixaban clearance 1
- Advanced age (≥80 years) with multiple comorbidities: May have unpredictable pharmacokinetics 6
Verification of Adequate Clearance
In high-risk situations or urgent procedures, consider measuring apixaban-calibrated anti-Xa levels if available. A level ≤30 ng/mL indicates clinically insignificant anticoagulation 7. However, this is not routinely necessary for elective procedures with proper timing.
Thromboembolic Risk
The short 48-72 hour interruption period carries minimal thromboembolic risk. The PAUSE study demonstrated 30-day arterial thromboembolism rates of only 0.16-0.60% with standardized DOAC interruption 8. For patients at very high thromboembolic risk (mechanical heart valve, recent stroke within 3 months), individualized assessment is needed, though these patients typically should not be on apixaban.